Answers are grounded in this paper and cite their sources.
In a double-blind study, indoprofen was superior to placebo in decreasing pain in patients with primary and metastatic cancer and with neuralgia. A single oral dose of 200 mg was more active than a 100-mg dose. The preferences of patients proved to be a more sensitive parameter in this study than scores of pain intensity, pain relief, and other related measurements (SPID, TOTPAR, and Peak PID).
No takes yet. Share an insight, caveat, or question.
Fuccella et al. (1975) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: